Jennerex Biotherapeutics

SillaJen completes Jennerex acquisition

Monday, March 17, 2014

SillaJen, a privately held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, has completed the acquisition of San Francisco-based Jennerex. Privately held Jennerex is a clinical-stage, biotherapeutics company developing best-in-class targeted oncolytic immunotherapies.

[Read More]

SillaJen to acquire Jennerex

Wednesday, November 27, 2013

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

[Read More]

Jennerex enrolls first patient in phase IIb liver cancer trial

Friday, November 4, 2011

Jennerex has initiated enrollment and the first patient has
been randomized in a phase IIb clinical trial called TRAVERSE.  The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC.  In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.

[Read More]